Table 1 Comparison of clinicopathological features between patients with and without Graves’ disease
Characteristics | PTC with GD (n = 114) | PTC without GD (n = 3514) | p value |
|---|---|---|---|
Age (years) | 46.3 ± 12.9 | 45.8 ± 12.2 | 0.641 |
Female sex | 99 (86.8%) | 2916 (83.0%) | 0.279 |
Body mass index (kg/m2) | 23.8 ± 3.1 | 23.5 ± 3.2 | 0.396 |
Preoperative FNA results | 0.197 | ||
Benign | 0 (0.0%) | 0 (0.0%) | |
Atypia | 7 (6.1%) | 62 (1.8%) | |
Follicular neoplasm | 0 (0.0%) | 166 (4.7%) | |
Suspicious malignancy | 30 (26.3%) | 841 (23.9%) | |
Malignancy | 77 (67.5%) | 2344 (66.7%) | |
Pathologic features | |||
Tumor size (cm) | 0.8 ± 0.5 | 0.9 ± 0.7 | 0.057 |
Extrathyroidal extension | 0.317 | ||
No | 59 (51.8%) | 1663 (47.3%) | |
Microscopic | 51 (44.7%) | 1611 (45.8%) | |
Gross | 4 (3.5%) | 240 (6.8%) | |
Lymphatic invasion | 2 (1.8%) | 234 (6.7%) | 0.037 |
Vascular invasion | 0 (0.0%) | 43 (1.2%) | 0.235 |
Margin involvement | 1 (0.9%) | 205 (5.8%) | 0.024 |
Number of retrieved LNs | 6.0 ± 5.8 | 6.7 ± 8.1 | 0.208 |
LN metastasis | 0.001 | ||
N0 | 80 (70.2%) | 2203 (62.7%) | |
N1a | 34 (29.8%) | 950 (27.0%) | |
N1b | 0 (0.0%) | 361 (10.3%) | |
131I remnant ablation | 43 (37.7%) | 1545 (44.0%) | 0.186 |
131I dose (mCi) | 47.2 ± 32.8 | 41.8 ± 35.8 | 0.331 |
Follow-up (months) | 96.8 ± 29.5 | 96.5 ± 31.0 | 0.894 |
Recurrence | 0.487 | ||
Regional recurrence | 1 (0.9%) | 62 (2.5%) | |
Distant metastasis | 0 (0.0%) | 5 (0.2%) | |